Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Heron Therapeutics (HRTX) over the last 11 years, with Q3 2025 value amounting to $81.0 million.

  • Heron Therapeutics' Receivables - Net rose 2089.53% to $81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.0 million, marking a year-over-year increase of 2089.53%. This contributed to the annual value of $78.9 million for FY2024, which is 3116.88% up from last year.
  • Latest data reveals that Heron Therapeutics reported Receivables - Net of $81.0 million as of Q3 2025, which was up 2089.53% from $79.9 million recorded in Q2 2025.
  • Heron Therapeutics' Receivables - Net's 5-year high stood at $81.0 million during Q3 2025, with a 5-year trough of $35.5 million in Q4 2021.
  • Its 5-year average for Receivables - Net is $58.5 million, with a median of $60.1 million in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Receivables - Net tumbled by 1517.56% in 2021 and then surged by 9029.1% in 2023.
  • Over the past 5 years, Heron Therapeutics' Receivables - Net (Quarter) stood at $35.5 million in 2021, then skyrocketed by 46.62% to $52.0 million in 2022, then rose by 15.54% to $60.1 million in 2023, then surged by 31.17% to $78.9 million in 2024, then rose by 2.75% to $81.0 million in 2025.
  • Its last three reported values are $81.0 million in Q3 2025, $79.9 million for Q2 2025, and $78.7 million during Q1 2025.